Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

ConditionsSolid Tumor Hematological Malignancy

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorInstitut Bergonié

About this trial

This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease.

In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling.

Patients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.

Eligibility criteria

Qualifiers

Age ≥ 18 years,

Histology: solid malignant tumor or hematological malignancy,

Deleted MSA9

Deleted MSA9,

Disqualifiers

Deleted MSA9

Trial design

Treatments tested in this trial

Newly obtained biopsy and Blood samples collection

Treatment groups

10,000 Participants

are divided into 1 treatment group

Sponsors and collaborators

Institut Bergonié

Lead sponsor

Source ClinicalTrials.gov